Evrofarma Statistics

Total Valuation

Evrofarma has a market cap or net worth of EUR 26.59 million. The enterprise value is 40.22 million.

Market Cap	26.59M
Enterprise Value	40.22M

Important Dates

The last earnings date was Wednesday, April 23, 2025.

Earnings Date	Apr 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Evrofarma has 13.67 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	13.67M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 11.66.

PE Ratio	11.66
Forward PE	n/a
PS Ratio	0.58
PB Ratio	1.49
P/TBV Ratio	1.50
P/FCF Ratio	6.44
P/OCF Ratio	4.97
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.81, with an EV/FCF ratio of 9.75.

EV / Earnings	17.64
EV / Sales	0.88
EV / EBITDA	6.81
EV / EBIT	9.86
EV / FCF	9.75

Financial Position

The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.95.

Current Ratio	0.97
Quick Ratio	0.59
Debt / Equity	0.95
Debt / EBITDA	2.87
Debt / FCF	4.11
Interest Coverage	3.42

Financial Efficiency

Return on equity (ROE) is 13.39% and return on invested capital (ROIC) is 7.23%.

Return on Equity (ROE)	13.39%
Return on Assets (ROA)	5.34%
Return on Invested Capital (ROIC)	7.23%
Return on Capital Employed (ROCE)	13.61%
Revenue Per Employee	275,416
Profits Per Employee	13,735
Employee Count	156
Asset Turnover	0.96
Inventory Turnover	5.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.47% in the last 52 weeks. The beta is 0.83, so Evrofarma's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	+16.47%
50-Day Moving Average	1.88
200-Day Moving Average	1.66
Relative Strength Index (RSI)	62.00
Average Volume (20 Days)	10,641

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evrofarma had revenue of EUR 45.72 million and earned 2.28 million in profits.

Revenue	45.72M
Gross Profit	9.23M
Operating Income	4.08M
Pretax Income	2.89M
Net Income	2.28M
EBITDA	5.85M
EBIT	4.08M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 3.32 million in cash and 16.95 million in debt, giving a net cash position of -13.63 million or -1.00 per share.

Cash & Cash Equivalents	3.32M
Total Debt	16.95M
Net Cash	-13.63M
Net Cash Per Share	-1.00
Equity (Book Value)	17.83M
Book Value Per Share	n/a
Working Capital	-461,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.35 million and capital expenditures -1.23 million, giving a free cash flow of 4.13 million.

Operating Cash Flow	5.35M
Capital Expenditures	-1.23M
Free Cash Flow	4.13M
FCF Per Share	0.30

Full Cash Flow Statement

Margins

Gross margin is 20.20%, with operating and profit margins of 8.92% and 4.99%.

Gross Margin	20.20%
Operating Margin	8.92%
Pretax Margin	6.32%
Profit Margin	4.99%
EBITDA Margin	12.79%
EBIT Margin	8.92%
FCF Margin	9.03%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 2.63%.

Dividend Per Share	0.05
Dividend Yield	2.63%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	29.82%
Buyback Yield	n/a
Shareholder Yield	2.63%
Earnings Yield	8.57%
FCF Yield	15.52%

Dividend Details

Stock Splits

The last stock split was on July 26, 2001. It was a forward split with a ratio of 2.

Last Split Date	Jul 26, 2001
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a